Market Place
Sourcing Support
Alvotech Reports 2024 Results for First Nine Months Again
13 Nov 2024 //
GLOBENEWSWIRE
Alvotech Reports 2024 Results for First Nine Months
13 Nov 2024 //
GLOBENEWSWIRE
Alvotech to Attend Citi & Evercore Conferences in Dec 2024
07 Nov 2024 //
GLOBENEWSWIRE
EMA Accepts Marketing Application for AVT05 Biosimilar to Simponi®
04 Nov 2024 //
GLOBENEWSWIRE
Alvotech to Report 2024 Results on Nov 13, Call on Nov 14
30 Oct 2024 //
GLOBENEWSWIRE
Alvotech to Present at Jefferies 2024 London Healthcare Conference
25 Oct 2024 //
GLOBENEWSWIRE
Alvotech And Teva Announce FDA Approval Of SELARSDI™ Presentation
22 Oct 2024 //
GLOBENEWSWIRE
Alvotech`s Biologic Selarsi (Ustekinumab) Receives Approval in US
18 Oct 2024 //
FDA
EMA Accepts AVT03 Marketing Application For Prolia Biosimilar
10 Oct 2024 //
GLOBENEWSWIRE
Alvotech Initiates AVT16 Confirmatory Patient Study
25 Sep 2024 //
GLOBENEWSWIRE
Alvotech To Participate In Morgan Stanley Global Healthcare Conference
26 Aug 2024 //
GLOBENEWSWIRE
Alvotech`s Biologic Simlandi (Adalimumab) Receives Suppl Approvals in US
26 Aug 2024 //
FDA
EMA Accepts Marketing Application For AVT06, Biosimilar To Eylea (Aflibercept)
15 Aug 2024 //
GLOBENEWSWIRE
Alvotech Reports Record Revenues And Adjusted EBITDA For Q2 And H1 2024
15 Aug 2024 //
GLOBENEWSWIRE
Alvotech To Report H1 2024 Results On August 15
01 Aug 2024 //
GLOBENEWSWIRE
STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In Europe
23 Jul 2024 //
PHARMABIZ
STADA And Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar In EU
22 Jul 2024 //
GLOBENEWSWIRE
Alvotech Announces Closing of Private Debt Financing
11 Jul 2024 //
GLOBENEWSWIRE
Alvotech Reports Positive Results For AVT03, Biosimilar To Prolia And Xgeva
02 Jul 2024 //
GLOBENEWSWIRE
Alvotech Announces Record Q2 2024 Preliminary Revenue And EBITDA
01 Jul 2024 //
GLOBENEWSWIRE
Alvotech Issues New Shares to Holders of Convertible Bonds
01 Jul 2024 //
GLOBENEWSWIRE
Alvotech Receives Conversion Notices for Majority of Convertible Bonds
26 Jun 2024 //
GLOBENEWSWIRE
Alvotech & Advanz announce commercialisation agreement for Eylea biosimilar
18 Jun 2024 //
PHARMAFILE
Alvotech and STADA add to strategic alliance through denosumab partnership
12 Jun 2024 //
PRESS RELEASE
Alvotech Announces Strategic Refinancing Agreement
06 Jun 2024 //
GLOBENEWSWIRE
Alvotech At Jefferies Healthcare Conference In New York
29 May 2024 //
GLOBENEWSWIRE
Alvotech Reports Q1 2024 Results, Provides Business Update
21 May 2024 //
GLOBENEWSWIRE
Alvotech, Dr. Reddy`s ink pact for commercialisation of denosumab
21 May 2024 //
PRESS RELEASE
Teva, Alvotech`s SIMLANDI Adalimumab Biosimilar Now Available In US
20 May 2024 //
GLOBENEWSWIRE
Alvotech S.A. Annual General Meeting to be held June 7, 2024
15 May 2024 //
GLOBENEWSWIRE
Alvotech Announces Q1 2024 Results Webcast On May 22 At 8am EDT
13 May 2024 //
GLOBENEWSWIRE
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
08 May 2024 //
REUTERS
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
02 May 2024 //
GLOBENEWSWIRE
Quallent US Deal for Patient Savings with Humira® Biosimilar
30 Apr 2024 //
GLOBENEWSWIRE
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
25 Apr 2024 //
REUTERS
Alvotech`s AVT05 Simponi® Biosimilar Topline Results
24 Apr 2024 //
GLOBENEWSWIRE
Alvotech Signs US Deal To Expand Humira Biosimilar Access
19 Apr 2024 //
GLOBENEWSWIRE
Alvotech and Teva gain FDA approval of Selarsdi for psoriasis
17 Apr 2024 //
PHARMACEUTICAL TECHNOLOGY
Alvotech USA`s Biologic Selarsdi (ustekinumab-aekn) Receives Approval In US
16 Apr 2024 //
FDA
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™
16 Apr 2024 //
BUSINESSWIRE
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
03 Apr 2024 //
GLOBENEWSWIRE
Alvotech Announces Increase in Number of Own Shares
22 Mar 2024 //
GLOBENEWSWIRE
Alvotech Reports Financial Results for Full Year 2023
20 Mar 2024 //
GLOBENEWSWIRE
Alvotech Announces Webcast of Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Alvotech Appoints Interim Chief Quality Officer
29 Feb 2024 //
PRESS RELEASE
Alvotech Accepts Offer for the Sale of Shares for a value of USD 166 million
26 Feb 2024 //
GLOBENEWSWIRE
Teva and Alvotech`s Humira biosimilar finally snags FDA approval
24 Feb 2024 //
FIERCE PHARMA
Alvotech`s Biologic Simlandi (adalimumab) Receives Approval in the U.S.
23 Feb 2024 //
FDA
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar
15 Feb 2024 //
GLOBENEWSWIRE
FDA Issues Form 483 to Alvotech Hf
31 Jan 2024 //
FDA
Alvotech Announces Positive Results from a Pharmacokinetic Study for AVT03
29 Jan 2024 //
PRESS RELEASE
Transactions of Managers and Closely Associated Persons
24 Jan 2024 //
PRESS RELEASE
FDA doles out yet another Form 483 to troubled Alvotech
22 Jan 2024 //
FIERCE PHARMA
Alvotech Provides Update on Status of BLA for AVT02 and AVT04
19 Jan 2024 //
GLOBENEWSWIRE
STADA and Alvotech Secure Approval for Uzpruvo
10 Jan 2024 //
GLOBENEWSWIRE
Alvotech Study Results Demonstrate Therapeutic Equivalence between AVT06
03 Jan 2024 //
GLOBENEWSWIRE
Alvotech Announces Positive Results from a Pharmacokinetic Study for AVT05
29 Nov 2023 //
GLOBENEWSWIRE
Alvotech Reports Financial Results for First Nine Months of 2023
28 Nov 2023 //
GLOBENEWSWIRE
Alvotech to Report Financial Results for the First Nine Months of 2023
21 Nov 2023 //
GLOBENEWSWIRE
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki
14 Nov 2023 //
GLOBENEWSWIRE
